Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Abnormal Proliferation

Abnormal Proliferation

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026

Same author

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Same author

Exploring Environmental Element Monitoring Data Using Chemometric Techniques: A Practical Case Study from the Tremiti Islands (Italy).

Molecules (Basel, Switzerland)·2026

Same author

Identification and Characterization of ERK2 Dimerization Inhibitors by Integrated In Silico and In Vitro Screening.

International journal of molecular sciences·2025

Same author

Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Same author

Design of Experiments Approach for Efficient Heavy Metals Stabilization Using Metakaolin-Based Geopolymers.

Molecules (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Mar 19, 2026

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

Tumors topple when ERKs uncouple.

Ana Herrero¹, Piero Crespo²

¹Systems Biology Ireland, Conway Institute, University College Dublin , Belfield, Dublin, Ireland.

Molecular & Cellular Oncology

|June 17, 2016

Summary

Targeting the RAS-ERK pathway with a new inhibitor that blocks ERK dimerization shows promise in preventing tumor progression. This approach highlights the potential of targeting protein interactions for cancer therapy.

Keywords:

Antitumor therapy; dimerization inhibitor; ERK

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Induction and Analysis of Epithelial to Mesenchymal Transition

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Related Experiment Videos

Last Updated: Mar 19, 2026

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Induction and Analysis of Epithelial to Mesenchymal Transition

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Area of Science:

Oncology
Molecular Biology
Biochemistry

Background:

The RAS-ERK pathway is frequently dysregulated in various cancers.
Current therapies often target kinase activity within this pathway.
Inhibiting protein-protein interactions presents an alternative therapeutic strategy.

Purpose of the Study:

To investigate the efficacy of targeting ERK dimerization in tumors with oncogenic RAS and BRAF mutations.
To demonstrate the potential of targeting regulatory protein-protein interactions in cancer treatment.

Main Methods:

Utilized a small-molecule inhibitor designed to block ERK dimerization.
Assessed the inhibitor's effect on tumor progression in preclinical models harboring RAS-ERK pathway alterations.

Main Results:

The small-molecule inhibitor of ERK dimerization effectively halted tumor progression.
This demonstrates the therapeutic potential of targeting protein-protein interactions in the RAS-ERK pathway.

Conclusions:

Targeting ERK dimerization is a viable strategy for treating RAS-ERK pathway-driven cancers.
Disrupting regulatory protein-protein interactions offers a novel therapeutic avenue in oncology.